Document is current
Any future updates will be listed below
-
Authors
Wang, Yue
Mohammadi, Behnam
Hartmann, Christiane
Hartmann, Kristin
Thies, Edda
Matamoros-Angles, Andreu
Fang, Cheng
Harris, David A.
Tatzelt, Jörg
Altmeppen, Hermann C.
Sepulveda-Falla, Diego
Strittmatter, Stephen M.
Glatzel, Markus
Krasemann, Susanne
-
Funding
Funding for this research was provided by:
Universitätsklinikum Hamburg-Eppendorf (UKE)
- License Information
-
More Information
Article History
Received: 10 September 2025
Accepted: 15 January 2026
First Online: 29 January 2026
Declarations
:
: This work is entirely novel and not under considered elsewhere. All authors have approved the final version of the manuscript and agree with its submission and publication.
: SM.S. is founder, equity holder, director, and paid consultant of Allyx Therapeutics, which seeks to develop mGluR5 compounds for AD and holds a license for BMS-984923/ALX-001. The other authors declare that there is no conflict of interest with regard to this study.
